NCT00637143

Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 107 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare renal transplant recipients on cyclosporine maintenance therapy vs. those converted to tacrolimus-based immunosuppression with respect to renal outcomes.

Detailed description

The objective of this study is to compare the incidence, progression and severity of chronic renal allograft failure in at-risk patients who are converted from cyclosporine to tacrolimus-based immunosuppression to patients who remain on cyclosporine.

Conditions

• Renal Transplantation
• Chronic Renal Allograft Failure

Interventions

Type	Name	Description
DRUG	Tacrolimus	Oral
DRUG	Cyclosporine	Oral

Timeline

• Start date: 1999-04-01
• Primary completion: 2006-02-01
• Completion: 2006-02-01
• First posted: 2008-03-17
• Last updated: 2017-02-16

Locations

13 sites across 1 country: Canada